LACTOLOGY FOUNDATION

Benzilone (ATC A03AB01) is a synthetic quaternary-ammonium antimuscarinic antispasmodic used for functional gastrointestinal disorders, with limited modern clinical use and almost no specific data in breastfeeding; risk assessment in lactation relies on class effects of anticholinergics and general principles of medicine use in nursing mothers.medpedia.framar+5

Active substance and class

Benzilone is classified in the WHO ATC system as A03AB01, within “synthetic anticholinergics, quaternary ammonium compounds,” used for functional gastrointestinal disorders. It acts as an antimuscarinic (anticholinergic) agent, blocking acetylcholine at muscarinic receptors and thereby inhibiting parasympathetic activity.atcddd.fhi+4

Indications and clinical use

ATC A03AB01 benzilone is included among drugs for functional gastrointestinal disorders, particularly as an antispasmodic for intestinal motility and spasm-related symptoms. Contemporary practice guidelines for gastrointestinal antispasmodics more commonly reference agents such as hyoscine butylbromide, propantheline, peppermint oil, mebeverine, and alverine, suggesting benzilone has limited or legacy use in many markets.sps+2

Mechanism of action and pharmacology

Anticholinergic agents like benzilone block acetylcholine at muscarinic receptors in the enteric nervous system, reducing smooth muscle tone and motility and decreasing spasms in the gastrointestinal tract. As a quaternary ammonium compound, benzilone is expected to have poor lipid solubility and limited penetration across the blood–brain barrier, which may reduce central nervous system effects compared with tertiary amines.wikipedia+3

Dosage and administration

WHO ATC/DDD data list benzilone (A03AB01) with a defined daily dose (DDD) of 70 mg for oral administration, reflecting typical maintenance exposure for adults in chronic use contexts. Individual dosing regimens, titration, and treatment duration should be determined by a prescribing clinician based on indication, comorbidities, and concurrent therapy, as also emphasized in local reference entries.medpedia.framar+1

Toxicology and safety profile

Anticholinergic medications as a class can cause adverse effects related to parasympathetic inhibition, including dry mouth, blurred vision, constipation, urinary retention, tachycardia, and, at higher exposures, confusion or delirium, especially in vulnerable populations. Quaternary antimuscarinics like benzilone generally have reduced central nervous system penetration but still share systemic anticholinergic risks, particularly when combined with other anticholinergic agents or in overdose.ncbi.nlm.nih+3

Overdose and poisoning features

Toxicity from anticholinergic agents typically presents with “anticholinergic syndrome”: hyperthermia, flushed dry skin, mydriasis, tachycardia, urinary retention, ileus, agitation, and, in severe cases, seizures and cardiac arrhythmias. Management is primarily supportive (airway, circulation, temperature control, seizure management) and may include cautious use of a cholinesterase inhibitor (e.g., physostigmine) under specialist guidance in severe, clearly anticholinergic delirium.medsafe+1

Contraindications and cautions

Antimuscarinics are generally contraindicated in patients with known hypersensitivity to the drug or excipients, as explicitly noted for benzilone in local product information. Class-related cautions include narrow-angle glaucoma, urinary retention (e.g., prostatic hypertrophy), severe ulcerative colitis, intestinal obstruction, and tachyarrhythmias, where anticholinergic effects may exacerbate underlying conditions.ncbi.nlm.nih+3

Drug interactions

Anticholinergics can have additive effects when combined with other antimuscarinic drugs (e.g., tricyclic antidepressants, certain antihistamines, antipsychotics), increasing the risk of central and peripheral anticholinergic toxicity. Concomitant use with agents that slow gastrointestinal motility may increase the risk of ileus or reduced absorption of co-administered oral medications.sps+1

Use in pregnancy

There are no robust modern human pregnancy data specifically for benzilone, and older antispasmodics of this class were often used cautiously during pregnancy only when benefits outweighed potential risks. General recommendations for medicine use in pregnancy emphasize using the lowest effective dose, limiting duration, and preferring agents with more established safety profiles when alternatives exist.drugbank+4

Lactation pharmacology and exposure

No specific pharmacokinetic or clinical data were identified for benzilone in breastfeeding women or breastfed infants. General principles indicate that quaternary ammonium anticholinergics, due to their high polarity and limited oral bioavailability, may have relatively low transfer into milk and limited systemic absorption by the infant, but this cannot be confirmed for benzilone in the absence of direct measurements.drugbank+4

Class-based lactation safety assessment

Guidance on gastrointestinal antispasmodics during breastfeeding identifies hyoscine butylbromide, propantheline, and peppermint oil as preferred options, with mebeverine and alverine also acceptable; benzilone is not listed among preferred drugs, reflecting a lack of data and/or current clinical use. Broader lactation safety resources note that most medicines excreted into breast milk at less than 10% of the maternal dose are generally compatible with breastfeeding, though individual risk–benefit assessment is required.kellymom+3

Potential infant risks during breastfeeding

In theory, anticholinergic exposure via milk could cause infant adverse effects such as reduced gastrointestinal motility, constipation, urinary retention, or central effects (sedation, irritability) depending on dose and susceptibility. Premature infants, neonates, and infants with underlying cardiac, renal, or gastrointestinal disease may be at higher risk and warrant particular caution with any anticholinergic exposure.who+2

Practical recommendations in lactation

Given the absence of benzilone-specific lactation data and availability of other antispasmodics with more established breastfeeding safety, many reference sources recommend preferring better-studied alternatives when treating functional gastrointestinal disorders in nursing women. If benzilone use is considered essential, experts advise individualized assessment, using the lowest effective dose for the shortest duration, timing doses immediately after feeds where feasible, and monitoring the breastfed infant for anticholinergic effects.mayoclinic+4

Monitoring and counselling of breastfeeding dyads

When a breastfeeding mother receives any anticholinergic agent, clinicians should monitor the infant for changes in feeding, weight gain, stool pattern, level of alertness, and signs of constipation or urinary retention. Mothers should be counselled not to discontinue breastfeeding unnecessarily, but to seek prompt medical advice if infant adverse effects emerge, as most lactation-compatible medicines can be continued or switched without stopping nursing.medsafe+3

Summary for clinical practice

Benzilone (A03AB01) is an older quaternary antimuscarinic antispasmodic with limited contemporary use and a safety profile consistent with systemic anticholinergic agents, especially regarding cardiovascular, ocular, urinary, and gastrointestinal effects. In lactating patients, the absence of direct data and the availability of preferred alternatives mean benzilone should generally be avoided when other, better-characterised antispasmodics can achieve the same therapeutic goal, reserving its use for selected cases under specialist supervision and with close infant monitoring.drugs.ncats+7